Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BRAIN Biotech AG's revenue for the
three
months ended in Mar. 2026 was €11.48 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was €48.19 Mil.
BRAIN Biotech AG's Revenue per Share for the
three
months ended in Mar. 2026 was €0.53.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €2.21.
Warning Sign:
BRAIN Biotech AG revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of BRAIN Biotech AG was -8.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 0.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 4.30% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 5.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 11 years, BRAIN Biotech AG's highest 3-Year average Revenue per Share Growth Rate was 12.40% per year. The lowest was -3.00% per year. And the median was 8.00% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
BRAIN Biotech AG Revenue Related Terms
BRAIN Biotech AG Revenue Historical Data
* Premium members only.
The historical data trend for BRAIN Biotech AG's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Chemicals subindustry, BRAIN Biotech AG's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BRAIN Biotech AG Revenue vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's Revenue distribution charts can be found below:
* The bar in red indicates where BRAIN Biotech AG's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €48.19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BRAIN Biotech AG (HAM:BNN) has a Revenue of €48.19 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on BRAIN Biotech AG and its competitors.
Is BRAIN Biotech AG's Revenue too high?
BRAIN Biotech AG's current Revenue is €48.19 Mil. Overall, BRAIN Biotech AG has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BRAIN Biotech AG's Revenue compare to LIN and SHW?
BRAIN Biotech AG's Revenue of €48.19 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Chemicals company?
A good Revenue depends on the Chemicals industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on BRAIN Biotech AG and its competitors. BRAIN Biotech AG's current Revenue is €48.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRAIN Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, BRAIN Biotech AG (HAM:BNN) is currently considered Fairly Valued. The stock's GF Value™ is €2.53, compared to a current price of €2.77 — trading 9.5% above its estimated fair value. The current Revenue is €48.19 Mil. BRAIN Biotech AG's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For BRAIN Biotech AG (HAM:BNN), the current Revenue is €48.19 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BRAIN Biotech AG (HAM:BNN) Overvalued in 2026?
Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued.
The current stock price of €2.77 is trading 9.5% above its estimated GF Value™ of €2.53.
GuruFocus considers BRAIN Biotech AG to be Fairly Valued.
Key valuation signals for HAM:BNN:
Revenue: €48.19 Mil
GF Value™: €2.53 vs. price of €2.77 (9.5% above fair value)
No single metric tells the full story. See the HAM:BNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
68GF Score
Get the complete analysis for HAM:BNN
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:BNN has been successfully added to your 
